Compare
Black Hawk Acquisition Corp vs Pluri Inc. vs Champions Oncology, Inc. vs CEL SCI Corp
| Latest fiscal year | Black Hawk Acquisition Corp BKHA | Pluri Inc. PLUR | Champions Oncology, Inc. CSBR | CEL SCI Corp CVM |
|---|---|---|---|---|
| Year ended | 2025-11-30 | 2026-06-30 | 2026-04-30 | 2025-09-30 |
| Revenue | n/a | $1.02M | $59.42M | n/a |
| Revenue growth (YoY) | n/a | -24.0% | +4.4% | n/a |
| Gross margin | n/a | 44.6% | 48.0% (computed) | n/a |
| Operating margin | n/a | n/m | -1.9% | n/a |
| Net margin | n/a | n/m | -2.0% | n/a |
| Net income | $1.33M | -$23.82M | -$1.18M | -$25.41M |
| EPS (Diluted) | n/a | -$2.44 | -$0.08 | -$6.27 |
| Operating cash flow | -$650.3K | -$19.59M | -$4.47M | -$17.12M |
| Free cash flow | n/a | -$20.22M | -$5.04M | -$17.16M |
| Cash & equivalents | $0 | $3.53M | n/a | n/a |
| Total assets | $23.88M | $24.88M | $26.99M | $28.16M |
| Total liabilities | $3.90M | n/a | $22.92M | $12.20M |
| Shareholders' equity | -$3.85M | -$23.04M | $3.94M | $15.96M |
| Return on year-end equity | n/a | n/a | -29.8% | -159.2% |
| Shares outstanding | n/a | 10.82M | 13.89M | 8.02M |
Revenue, most recent five fiscal years
| Fiscal year | Black Hawk Acquisition Corp | Pluri Inc. | Champions Oncology, Inc. | CEL SCI Corp |
|---|---|---|---|---|
| Latest | n/a | $1.02M Ended 2026-06-30 | $59.42M Ended 2026-04-30 | $264.0K Ended 2014-09-30 |
| 1 year earlier | n/a | $1.34M Ended 2025-06-30 | $56.94M Ended 2025-04-30 | $159.6K Ended 2013-09-30 |
| 2 years earlier | n/a | $326.0K Ended 2024-06-30 | $50.16M Ended 2024-04-30 | $254.6K Ended 2012-09-30 |
| 3 years earlier | n/a | $287.0K Ended 2023-06-30 | $53.87M Ended 2023-04-30 | $956.2K Ended 2011-09-30 |
| 4 years earlier | n/a | $234.0K Ended 2022-06-30 | $49.11M Ended 2022-04-30 | n/a |